Search | Clinical Trials Finder

Conditions: Safety in Healthy Volunteers
Interventions: XmAb27564, Placebo; Drug
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GNS-3545, GNS-3545 Placebo; Drug
Lead sponsor: Genosco Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Crohn Disease
Interventions: TAK-018, TAK-018 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 16 more

Conditions: Atherosclerosis, Heterozygous Familial Hypercholesterolemia
Interventions: Pactimibe sulfate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Santa Ana, California • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Sports Performance, Vision, Ocular
Interventions: Senaptec Strobe Glasses, Standard softball drills; Device · Other
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Benign Prostatic Hyperplasia
Interventions: PRX302, Placebo; Drug · Other
Lead sponsor: Sophiris Bio Corp; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 45
States / cities: Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more

Conditions: Neuropathic Corneal Pain
Interventions: Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution; Drug · Other
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Degenerative Disc Disease
Interventions: IDCT (rebonuputemcel), Sham (No Treatment); Biological · Other
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Overactive Bladder (OAB)
Interventions: Tensi+; Device
Lead sponsor: Stimuli Technology; Industry
Eligibility: 22 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Beverly Hills, California • New York, New York

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Glendale, California + 20 more

Conditions: Poliomyelitis
Interventions: Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more

Conditions: Acne Vulgaris
Interventions: CD2475/101 40 mg, Doxycycline 100 mg, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more

Conditions: Tourette's Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Dothan, Alabama • San Francisco, California • Gainesville, Florida + 9 more

Conditions: Osteoarthritis, Pain
Interventions: Placebo, Fulranumab 1 mg, Fulranumab 3 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: El Cajon, California • Sherman Oaks, California • Miami, Florida + 4 more

Conditions: Healthy Adult Participants
Interventions: ARN-75039 oral capsules, Placebo; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: RSV Illness in ≤12 Months of Participants
Interventions: Motavizumab, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 0 Months to 12 Months
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: Tucson, Arizona • Long Beach, California • Orange, California + 23 more

Conditions: Cystic Fibrosis
Interventions: N6022, Normal saline; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 30 Years to 84 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more

Conditions: Glomerular Disease, Proteinuria
Interventions: ANG-3070, Placebo; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more

Conditions: Stress Urinary Incontinence
Interventions: Transcutaneous electrical stimulation (Elitone); Device
Lead sponsor: Elidah, Inc.; Industry
Eligibility: 21 Years to 75 Years · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Monroe, Connecticut

Conditions: Healthy
Interventions: BIIB033, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cardiometabolic Syndrome
Interventions: Aegis CDM Test and Educational Materials; Diagnostic Test
Lead sponsor: Qure Healthcare, LLC; Industry
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cocaine Dependence, Cocaine Addiction
Interventions: Metyrapone, Oxazepam, Placebo; Drug
Lead sponsor: Embera NeuroTherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Shreveport, Louisiana

Search by objective public record fields.

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

Stroboscopic Vision Training in Softball

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

Tensi+ for Treating Overactive Bladder

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Stress Incontinence Trial With Elitone Device

BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects

Establishing Clinical Utility Evidence for Chronic Disease Management Testing Patient Study

A Placebo-Controlled Study of a Combination of Metyrapone and Oxazepam in Cocaine Addiction